-

CEO, Jakob Lindberg, will attend the Nordic Life Science Days, 14-15 September 2016 in Stockholm Sweden.

Oncopeptides presented clinical results from a Phase 2 study of melflufen and dexamethasone in patients with relapsed-refractory multiple myeloma at the 21th European Hematology Association Congress in Copenhagen, Denmark, June 7 – 11.

The results can be downloaded below.

The results further support Oncopeptides’ belief that melflufen has the potential to make a meaningful difference in the lives of patients with relapsed-refractory multiple myeloma, providing a reliable go-to alternative even when conventional therapies have failed”.

For further information or to arrange a meeting for discussions please contact Jakob Lindberg (CEO) or Björn Hammarberg (BD).

Upcoming events

Annual General Meeting 2022

The Annual General Meeting in Oncopeptides AB (publ) will be held on Tuesday June 28, 2022, (changed from May 19, 2022) in Stockholm, Sweden. Due to the extraordinary situation resulting from the covid-19 pandemic, Oncopeptides’ Annual General Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting with the possibility to attend in person or to be represented by a proxy will take place. Hence, the Annual General Meeting will be held without physical presence.

Silent Period

-

Silent Period

-

Silent Period

-

Year-end report 2022

08:00 CET